CUMULATIVE INDEX

February-May

Page numbers of clinic and symposium titles are given in **boldface** type.

ABDOMEN, cysts, sites of origin, *May*, 415
tumors of, analysis, *May*, 414
Abnormalities, developmental, congenital, *May*, 573
Acetone, blood, bedside test for, *Feb.*, 319
Achalasia, *May*, 409
Acid, organic, concentration of, in fasting infant, *Feb.*, 54
Acid-base, disturbances, in salicylate intoxication, treatment, *Feb.*, 295–6
urine and body fluids in, *Feb.*, 73
equilibrium, disturbance of, in salicylism, *Feb.*, 285–7
Acidification of urine, *Feb.*, 69–73
Acidosis. See also *Alkalosis.*
and alkalosis, *Feb.*, **19–27**
compensated, *Feb.*, 26
diabetic. See under *Diabetes mellitus.*
dilutional, *Feb.*, 296
metabolic, in newborn, *Feb.*, 182*ff.*
potassium losses with, *Feb.*, 94
symptoms and signs, *Feb.*, 26
urine and body fluids in, *Feb.*, 73
physical signs, *Feb.*, 103
respiratory, in cystic fibrosis of pancreas, *Feb.*, 236–7
symptoms and signs, *Feb.*, 26
urine and body fluids in, *Feb.*, 73
Aciduria, paradoxical, *Feb.*, 282, 293
ACTH. See *Adrenocorticotropic hormone.*
Addison's disease, adrenocortical failure due to, *Feb.*, 212–13
Adenoma, basophilic, *May*, 584
chromophobe, *May*, 584
nasal, *May*, 370
pituitary, eosinophilic, *May*, 584, 585
Adenoma sebaceum, *May*, 376
Adrenal steroids in acute leukemia, *May*, 617
Adrenals. See also *Cushing's syndrome.*
aplasia, primary, adrenocortical failure due to, *Feb.*, 210
cortex, failure. See *Adrenals, cortex, insufficiency.*
hyperplasia, congenital virilizing, adrenocortical failure due to, *Feb.*, 212
insufficiency, *Feb.*, 209–19
fluid therapy in, *Feb.*, **209–19**
fluid therapy, *Feb.*, 213–18
steroids of, in renal regulation of body fluids, *Feb.*, 74, 75
tumors of, *May*, 592–7
feminizing, *May*, 595–6
in females, *May*, 596
in males, *May*, 595–6
virilizing, *May*, 592–3
crisis, acute, adrenocortical failure due to, *Feb.*, 212
treatment, *Feb.*, 215
hemorrhage, adrenocortical failure due to, *Feb.*, 211
hormones, in adrenocortical failure, *Feb.*, 215–16
hyperplasia, congenital, vs. virilizing tumor, *May*, 593
hypofunction, adrenocortical failure due to, *Feb.*, 211
medulla, tumors of, *May*, 597–9
tumors, rest, *May*, 603–604
Adrenocorticotropic hormone in acute leukemia, *May*, 617, 623–4
Albumin, serum, in nephrotic syndrome, *Feb.*, 130

Aldosteronism, primary, *May*, 596–7
secondary, *May*, 596
Alimentary tract. See *Gastrointestinal tract*.
Alkalosis. See also *Acidosis*.
acidosis and, *Feb.*, **19–27**
compensated, *Feb.*, 26
metabolic, acidification of urine in, *Feb.*, 72, 73
in potassium deficiency, *Feb.*, 93
symptoms and signs, *Feb.*, 26
with potassium depletion, urine and body fluids in, *Feb.*, 73
respiratory, in salicylism, *Feb.*, 287
symptoms and signs, *Feb.*, 26
urine and body fluids in, *Feb.*, 73
symptoms and signs, *Feb.*, 26, 103
Ameloblastoma, *May*, 374, 375
melanotic, *May*, 375
Amethopterin in acute leukemia, *May*, 617
intrathecal, *May*, 621–23
Ammonia formation in conservation of base, *Feb.*, 22–3
Ammonium production, acidification of urine due to, *Feb.*, 71, 72
Androgen-producing tumors, *May*, 602–604
Anemia in acute leukemia, treatment, *May*, 614–15
Aneurysm, mediastinal, *May*, 396–400
Angiofibroma, nasopharyngeal, juvenile, *May*, 371, 372
Angiography. See under *Brain*.
Angioma of soft tissues, *May*, 552
Antidiuretic hormone, in renal regulation of body fluids, *Feb.*, 74
in water conservation, *Feb.*, 60, 61, 62
Antimetabolites in acute leukemia, *May*, 617, 620–23
Aorta, aneurysm, *May*, 396
Aortic arch, double, *May*, 400
Appendectomy, electrolyte solutions after, *Feb.*, 161
Appendix, tumors, *May*, 420
Aramine Bitartrate. See *Metaraminol bitartrate*.
Arrhenoblastoma, *May*, 499, 603
Arteries, pulmonary, aneurysm of, *May*, 398, 400
Astrocytoma, *May*, 354
Axilla, cystic hygroma, *May*, 530–35
Azotemia in acute renal failure, *Feb.*, 135

BASE, conservation of, *Feb.*, 23–4
by ammonia formation, *Feb.*, 22–3
Bed rest in cardiac failure, *Feb.*, 253
Bedside laboratory techniques, *Feb.*, **317–20**
Bicarbonate. See *Sodium bicarbonate*.
Bicarbonate-carbonic acid system in maintenance of pH, *Feb.*, 21–2
Bladder, tumors, *May*, 504–507
Blood, acetone level, bedside test for, *Feb.*, 319
capillary, blood-drawing technique, *Feb.*, 325–7
chemical determinations in newborn, limitations, *Feb.*, 183–4
chemical patterns in newborn, *Feb.*, 182–3
plasma, chemical studies in newborn, *Feb.*, 182
in adrenocortical failure, *Feb.*, 214
protein, increase in, solutions for, *Feb.*, 309–10
substitutes, *Feb.*, 310
pressure, in congestive cardiac failure, *Feb.*, 243
transfusion, in anemia of acute leukemia, *May*, 615
in chronic renal failure, *Feb.*, 133
in diarrhea in newborn, *Feb.*, 190
venous, blood-drawing technique, *Feb.*, 322–5
volume, increase in, solutions for, *Feb.*, 309–10
Blood-drawing techniques, *Feb.*, **321–8**
Blood vessels, great, congenital anomalies, *May*, 400
Body, chemical constituents, *Feb.*, 9
content, dietary intake and growth requirements correlated with, *Feb.*, 9
fluids. See under *Fluids*.
mechanisms for maintenance of pH, *Feb.*, 20–24
water, total, and normal electrolyte composition, *Feb.*, **5–18**
Bones, lesions, reactive, vs. tumor, *May*, 569
tumors, *May*, **557–71**
diagnosis, *May*, 557–8
differential diagnosis, *May*, 566–70
morphology, *May*, 560–61
roentgen examination, *May*, 558–60
symptoms and signs, *May*, 557, 558
Brain, angiography, in tumors of central nervous system, *May*, 352
electroencephalography, in tumors of central nervous system, *May*, 349–50
pneumoencephalography, in tumors of central nervous system, *May*, 351
Brain stem, glioma of, *May*, 355

Breast, hypertrophy, unilateral, idiopathic, *May*, 553
Brenner tumors, *May*, 500
Bronchogenic cyst, *May*, 407–408
carinal, *May*, 408
hilar, *May*, 408
paraesophageal, *May*, 408
paratracheal, *May*, 408
Buffers in maintenance of pH, *Feb.*, 20–22
Burns, *Feb.*, 169–77
fluid replacement, rationale of, *Feb.*, 173–5
fluid therapy in, *Feb.*, 175–7
trauma and shock, fluid therapy in, *Feb.*, 169–79
Busulfan in chronic granulocytic leukemia, *May*, 629

Calcium, content, of body, *Feb.*, 9, 14–15
intake, correlated with body content and growth requirements, *Feb.*, 9
requirements, *Feb.*, 38
therapy, in infant diarrhea, *Feb.*, 204
Calcium chloride in hypertonic dehydration, *Feb.*, 207
Calcium gluconate, in acute renal failure, *Feb.*, 135, 136
in chronic renal failure, *Feb.*, 133
in hypernatremic dehydration, *Feb.*, 199
in hypertonic dehydration, *Feb.*, 206, 207
Calcium lactate in hypertonic dehydration, *Feb.*, 207
Calories, daily requirements in newborn, *Feb.*, 185
expenditure, *Feb.*, 33
solutions for provision of, *Feb.*, 307–8
Cannulation, venous, *Feb.*, 313–14
Capillary blood-drawing technique, *Feb.*, 325–7
Carbohydrate. See also *Glucose*.
in acute renal failure, *Feb.*, 135
metabolism, disturbance in, in salicylate intoxication, *Feb.*, 284–5
Carbonate content of body, *Feb.*, 9, 16
Carbon dioxide, content, *Feb.*, 19
partial pressure, *Feb.*, 19
alveolar, *Feb.*, 282
arterial, *Feb.*, 282
tension, *Feb.*, 19
total, *Feb.*, 19
Carbon dioxide-combining power, *Feb.*, 19
Carbonic acid in maintenance of pH, *Feb.*, 22
Carcinoma, cystic, adenoid, *May*, 368, 376
embryonal, of testes, *May*, 500–501
mucoepidermoid, *May*, 368
nasopharyngeal, *May*, 370
of colon, *May*, 422
renal, clear cell. See *Hypernephroma*.
Cardiospasm. See *Achalasia*.
Cardiovascular collapse in infections, *Feb.*, 152
Catabolism, tissue, in potassium deficits, *Feb.*, 92
Cells, changes, in acidosis and alkalosis, *Feb.*, 25
membranes, metabolic transfer across, *Feb.*, 150–51
Cervix, tumors, *May*, 504–507
Chemical constituents of body, *Feb.*, 9
Chemodectoma, *May*, 372
Chemotherapy in acute leukemia, *May*, 616–24
agents, choice of, *May*, 618
principal, *May*, 617
Chlorambucil in Hodgkin's disease, *May*, 631, 634
Chloride, content, of body, *Feb.*, 9, 12–13
of gastric juice in ileostomy patients, *Feb.*, 162
in fluid therapy, after appendectomy, *Feb.*, 161
after herniorrhaphy, *Feb.*, 161
in preoperative fluid therapy, *Feb.*, 158
in newborn, *Feb.*, 159
in salicylate poisoning, *Feb.*, 293
in sweat in cystic fibrosis of pancreas, *Feb.*, 222
requirements, in diarrhea with dehydration, *Feb.*, 39
in parenteral fluids, *Feb.*, 32, 33
sweat, screening tests, *Feb.*, 230–31
tubular transport, *Feb.*, 50, 51
Chlorothiazide in congestive cardiac failure, *Feb.*, 251, 252
Chondroblastoma, benign, vs. osteosarcoma, *May*, 569
Chondrosarcoma vs. osteosarcoma, *May*, 568
Chordoma, *May*, 372, 373
Choriocarcinoma, *May*, 600–601
Chorio-epithelioma. See *Choriocarcinoma*.
Choroid plexus, tumors of, *May*, 356–7
Coat's disease vs. retinoblastoma, *May*, 362
Codman's triangle, *May*, 559

Codman's tumor. See *Chondroblastoma, benign.*
Colitis, ulcerative, carcinoma of colon in, *May*, 422
Collapse, cardiovascular, in infections, *Feb.*, 152
Colon, polyposis, multiple, hereditary, *May*, 421, 422
  tumors, *May*, 420–23
Coma in diabetic acidosis, *Feb.*, 117
Convulsions, in hypernatremic dehydration, *Feb.*, 198
  in infections, *Feb.*, 150
Corticosteroids, adrenal, in acute leukemia, *May*, 623–4
Cortisone acetate in prevention of adrenal crisis, *Feb.*, 217
Craniopharyngioma, *May*, 355–6
Cranium. See also *Brain; Head.*
  base of, teratoma of, *May*, 576
Cushing's syndrome, *May*, 594–5
    adrenal rest tumors in, *May*, 604
    laboratory data, *May*, 595
    treatment, *May*, 595
Cyanocobalamin in treatment of neuroblastoma, *May*, 457–65
    regression among survivors, *May*, 463
    regression in fatal cases, *May*, 461
    without obvious response, *May*, 460
Cyanosis in congestive cardiac failure, *Feb.*, 243, 244
Cylindroma. See *Carcinoma, cystic, adenoid.*
Cyst, abdominal, sites of origin, *May*, 415
  bronchogenic, *May*, 407–408
  dermoid, *May*, 377, 385
  epidermoid, *May*, 376
  follicular, *May*, 495–7
  gastroenteric, *May*, 404
  lymphatic, of mesentery and omentum, *May*, 535–7
  neurenteric, *May*, 404–406
    vs. intrathoracic meningocele, *May*, 410
  nonparastic, of liver, *May*, 439–41
  of pancreas, *May*, 423
  ovarian, *May*, 601–602
  pericardial, *May*, 387–8
Cystadenoma lymphomatosum, papillary, *May*, 368

Darrow's K lactate solution, in diarrhea, *Feb.*, 110
    in hypotonic dehydration, *Feb.*, 110
Darrow's K lactate solution, in hypotonic dehydration, due to diarrhea, *Feb.*, 107
    in isotonic dehydration, *Feb.*, 109
      due to diarrhea, *Feb.*, 105
Dehydration, *Feb.*, 82–7
  clinical considerations, *Feb.*, 87–96
  due to diarrhea, *Feb.*, 38–40
  due to hypertrophic pyloric stenosis, deficit therapy, *Feb.*, 113
  hypernatremic, *Feb.*, **193–9.** See also *Dehydration, hypertonic.*
  hypertonic, *Feb.*, 83, 85–6
    clinical considerations, *Feb.*, 91–2
    due to diarrhea, deficit therapy, *Feb.*, 108, 109
    in diarrhea, *Feb.*, 206, 207
    in neurologic disease, *Feb.*, **257–79**
    osmotic diuresis in, *Feb.*, 69
  hyponatremic. See *Dehydration, hypotonic.*
  hypotonic, *Feb.*, 83, 85
    clinical considerations, *Feb.*, 90–91
    due to diarrhea, deficit therapy, *Feb.*, 107, 109
    due to low sodium glucose, *Feb.*, 91
    urine concentration in, *Feb.*, 65, 66
  intracellular, *Feb.*, 94
    potassium deficits and, *Feb.*, 92–6
    treatment, *Feb.*, 95, 96
  isotonic, *Feb.*, 83, 84–5
    clinical considerations, *Feb.*, 88–90
    due to diarrhea, deficit therapy, *Feb.*, 105, 109
  physical signs, *Feb.*, 101, 102
  salt depletion and potassium loss, theoretical considerations, *Feb.*, **81–98**
  therapy, deficit, historical data in, *Feb.*, 101
  water and electrolyte deficits, *Feb.*, 100
Dermoid, ovarian, *May*, 578
Desoxycorticosterone acetate, in adrenal crisis, *Feb.*, 215
    in prevention of adrenal crisis, *Feb.*, 217
Desoxycorticosterone trimethylacetate in adrenal crisis, *Feb.*, 215, 216
Development, anomalies of, congenital, *May*, 573
Diabetes mellitus, acidosis, *Feb.*, 115–22
    fluid therapy, *Feb.*, **115–22**
    metabolic derangements, *Feb.*, 115–18
    osmotic diuresis in, *Feb.*, 68, 69
Diagnosis, differential, of mediastinal masses, *May*, **379–412**
Diaphragm, hernia of. See *Hernia, diaphragmatic.*

Diarrhea, acidosis due to, *Feb.*, 24
and vomiting, fluid therapy, *Feb.*, **99–114**
calcium therapy, *Feb.*, 204
complications, postacidotic, *Feb.*, **201–8**
dehydration due to, *Feb.*, 38–40
fluid therapy, *Feb.*, 104–11
in newborn, fluid therapy, *Feb.*, 189, 190
laboratory data, *Feb.*, 103
water and electrolyte deficits in, *Feb.*, 100
Diatrizoate sodium in excretory urography, *May*, 477
Diet, intake, correlation with body content and growth requirements, *Feb.*, 9
Digitalis, in congestive cardiac failure, *Feb.*, 246–51
preparations, *Feb.*, 250
Digitoxin, digitalizing doses, *Feb.*, 249
in congestive cardiac failure, *Feb.*, 249
Digoxin in congestive cardiac failure, *Feb.*, 249
Diuresis, osmotic, *Feb.*, 67–9
Diuretics in cardiac failure, *Feb.*, 251–3
Diuril. See *Chlorothiazide*.
DOCA. See *Desoxycorticosterone acetate*.
Drusen of optic nerve head and retina vs. retinoblastoma, *May*, 362, 363
Dysgerminoma, *May*, 498, 601

EAR, tumors of, *May*, 369–74
Edema, in congestive cardiac failure, *Feb.*, 244
pulmonary, acute, in salicylate poisoning, *Feb.*, 297
Electroencephalography. See under *Brain*.
Electrolyte, abnormality, in cystic fibrosis of pancreas, *Feb.*, **221–40**
composition, balance technique, *Feb.*, 6, 7
dilution technique, *Feb.*, 7, 8
gravimetric macromethods, *Feb.*, 6
normal, and total body water, *Feb.*, **5–18**
concentration, of sweat, *Feb.*, 228
content, of gastrointestinal fluids in newborn, *Feb.*, 188
of sweat, *Feb.*, 146
deficits, in dehydration, *Feb.*, 100
lacrimal, in cystic fibrosis of pancreas, *Feb.*, 224
needs, in newborn, *Feb.*, 181–4
requirements, in newborn, *Feb.*, 186
Electrolyte, salivary, in cystic fibrosis of pancreas, *Feb.*, 223
solutions, excessive administration, in hypernatremic dehydration, *Feb.*, 194–5
for fluid therapy, composition of, *Feb.*, 302
in burns, *Feb.*, 176–7
solutions for provision of, *Feb.*, 304–7
sweat, in cystic fibrosis of pancreas, *Feb.*, 221–4
tracheobronchial, in cystic fibrosis of pancreas, *Feb.*, 224
Embryoma, *May*, 574
retroperitoneal, of renal anlage origin, *May*, 487
Encephalocele vs. nasal glioma, *May*, 369
Endocrine glands, tumors, *May*, **583–608**
Enucleation in retinoblastoma, *May*, 364
Enzymes, changes in, in acidosis and alkalosis, *Feb.*, 25
Ependymoma, *May*, 353–4
Epignathus, *May*, 373, 576
Epinephrine in adrenal crisis, *Feb.*, 215, 216
Epithelioma, calcifying, *May*, 377
Epithelioma adenoides cysticum. See *Trichoepithelioma*.
Epulis, congenital, *May*, 373
Esophagus, lesions of, *May*, 409–10
stricture, lye, *May*, 416
tumors, *May*, 415–16
Estrogen-producing tumors, *May*, 599–602
Ewing's tumor, *May*, 564–6
roentgen findings, *May*, 565
symptoms and signs, *May*, 564, 565
treatment, *May*, 566
Exhaustion, adrenocortical failure due to, *Feb.*, 212
Extracellular fluids. See under *Fluids, body*.
Extremities, lymphangiomas, *May*, 537–9

FACE. See also *Head*; *Mouth*; *Nose*.
lymphangiomas, *May*, 537–9
Fat pad vs. pericardial cyst, *May*, 387
Feces, water losses in, in hypernatremic dehydration, *Feb.*, 194
Fever in infections, *Feb.*, 143–9
Fibroma, chondromyxoid, vs. bone tumor, malignant, *May*, 569–70
odontogenic, *May*, 375
Fibromatosis, juvenile, *May*, 552
Fibromyxosarcoma, *May*, 548
Fibrosarcoma. See under *Sarcoma*.

Fibrosis, retinal, massive, vs. retinoblastoma, *May*, 361
First aid in burns, *Feb.*, 170
Fluids. See also *Water*.
and electrolyte problems, clinical applications, *Feb.*, 99–299
physiologic considerations, *Feb.*, 5–98
symposium on, *Feb.*, **1–328**
technical procedures, *Feb.*, 301–28
body, extracellular, expansion of volume of, in salicylate poisoning, *Feb.*, 294
volume, reduction in, *Feb.*, 87, 88
in acid-base disturbances, *Feb.*, 73
intracellular, volume of, contraction, *Feb.*, 88
expanded, *Feb.*, 88
regulation of, renal structure and function related to, *Feb.*, **43–80**
volume regulation, *Feb.*, 75–6
gastrointestinal, electrolyte content in newborn, *Feb.*, 188
in acute renal failure, *Feb.*, 134, 135
intake, in burns, *Feb.*, 175
intravenous, in adrenal crisis, *Feb.*, 215
parenteral, in diabetic acidosis, *Feb.*, 119–22
requirements, physiologic basis, *Feb.*, **29–41**
principles of, *Feb.*, 31–4
therapy, techniques, *Feb.*, 311–15
replacement, in burns, rationale of, *Feb.*, 173–5
requirements, in diarrhea with dehydration, *Feb.*, 39
restriction, in cardiac failure, *Feb.*, 253
therapy, concomitant replacement of abnormal losses, *Feb.*, 99
deficit, *Feb.*, 99
during operative period, *Feb.*, 160
in adrenocortical failure, *Feb.*, **209–19**
in burns, *Feb.*, 175–7
in congestive circulatory failure, *Feb.*, **241–55**
in diabetic acidosis, *Feb.*, **115–22**
in neurologic disease, complications of, *Feb.*, **257–78**
in newborn infants, *Feb.*, **181–92**
in renal disease, *Feb.*, **123–37**
principles of, *Feb.*, 127–8
in shock, *Feb.*, 177–9
in surgical conditions, *Feb.*, **155–67**
in trauma, *Feb.*, 177–9
maintenance, *Feb.*, 99
in salicylate poisoning, *Feb.*, 295
Fluids, therapy, of diarrhea and vomiting, *Feb.*, **99–114**
postoperative, *Feb.*, 160–65
preoperative, *Feb.*, 157–9
solutions, *Feb.*, 301–10
and techniques, *Feb.*, **301–15**
classification, *Feb.*, 309
techniques, *Feb.*, 310–15
intravenous, *Feb.*, 311–12
parenteral, *Feb.*, 311–15
subcutaneous, *Feb.*, 314–15
Fluorohydrocortisone in adrenal crisis, *Feb.*, 216
Fructose in acute renal failure, *Feb.*, 134

Ganglioneuroma, *May*, 403
Gastric juice. See *Stomach, secretion*.
Gastrointestinal fluids in newborn, electrolyte content, *Feb.*, 188
Gastrointestinal tract and pancreas, tumors of, *May*, **413–26**
duplications, *May*, 419, 420
site of origin, *May*, 415
fluid therapy, *Feb.*, 310–11
Gavage, fluid therapy by, *Feb.*, 310–11
Genitourinary tract, lower, tumors of, *May*, **491–509**
Gigantism, pituitary, *May*, 584
Glioma, nasal, *May*, 369, 576
of brain stem, *May*, 355
Glomeruli. See under *Kidneys*.
Glomerulonephritis. See *Nephritis, glomerular*.
Glucose, in acute renal failure, *Feb.*, 134, 135
in chronic renal failure, *Feb.*, 132
in dehydration due to hypertrophic pyloric stenosis, *Feb.*, 113
in diabetic acidosis, *Feb.*, 119, 120, 121
in diarrhea, *Feb.*, 110
in newborn, *Feb.*, 190
in fluid therapy of burns, *Feb.*, 175
in hypernatremic dehydration, *Feb.*, 198
in hypertonic dehydration due to diarrhea, *Feb.*, 108
in hypotonic dehydration, *Feb.*, 110
due to diarrhea, *Feb.*, 107
in isotonic dehydration, *Feb.*, 109
due to diarrhea, *Feb.*, 105
in operative period fluid therapy, *Feb.*, 160
in potassium deficiency, *Feb.*, 37
in salicylate poisoning, *Feb.*, 295

Glycogenesis in potassium deficits, *Feb.*, 92–3
Goiter, intrathoracic, *May*, 389–90
Granuloma, eosinophilic, *May*, 372
vs. bone tumor, *May*, 568, 569
Granulosa cell tumor, *May*, 497–8, 600
Grawitz's tumor. See *Hypernephroma*.
Groin, cystic hygroma, *May*, 530
Growth, requirements, and body content, dietary intake correlated with, *Feb.*, 9

HAMARTOMA, *May*, 573–4
mesenchymal, of liver, *May*, 438–9
of bone, vs. bone tumor, *May*, 569
Hand-Schüller-Christian disease vs. bone tumor, *May*, 568, 569
Hartmann's solution, in isotonic dehydration, *Feb.*, 36
in potassium deficiency, *Feb.*, 37
Head. See also *Brain*; *Face*; *Neck*.
and neck, tumors of, *May*, 367–78
Heart, failure. See *Heart, insufficiency*.
insufficiency, congestive, *Feb.*, 241–55
fluid therapy in, *Feb.*, 241–55
murmurs, in congestive failure, *Feb.*, 243
sounds, in congestive failure, *Feb.*, 243
Heat. See also *Burns*.
effects, *Feb.*, 234
elimination, in infections, *Feb.*, 144–7
production, in infections, *Feb.*, 143–4
Heat prostration, treatment, *Feb.*, 235–6
Hemangioendothelioma, infantile, of liver, *May*, 437–8
of pancreas, *May*, 423
Hemangioma, *May*, 511–28
clinical manifestations, *May*, 516–20
course, *May*, 512–16
in infants, management, *May*, 511–28
of larynx, *May*, 374
of liver, *May*, 436–7
of parotid gland, *May*, 368, 369
of tongue, *May*, 373
regression, spontaneous, *May*, 526–7
treatment, *May*, 520–27
aim of, *May*, 520–22
complications, *May*, 522
principles of, *May*, 525–6
results, *May*, 526
type, identification of, *May*, 520
Hemoglobin, in maintenance of pH, *Feb.*, 22
increase in, solutions for, *Feb.*, 309–10
Hemorrhage, adrenal, adrenocortical failure due to, *Feb.*, 211
gastrointestinal, causes of, *May*, 415
Hernia, diaphragmatic, *May*, 390–92, 410
esophageal, *May*, 409
paraesophageal, *May*, 409
Herniorrhaphy, electrolyte solution after, *Feb.*, 161
Hiatus hernia. See *Hernia, diaphragmatic*.
Histamine in diagnosis of pheochromocytoma, *May*, 598
History in diarrhea and vomiting, *Feb.*, 101
Hodgkin's disease, *May*, 392, 630–33
clinical manifestations, *May*, 630–31
treatment, *May*, 631–3, 634
Hormone, adrenocorticotropic. See *Adrenocorticotropic hormone*.
excretion, in androgen-producing tumors, *May*, 602–603
in renal regulation of body fluids, *Feb.*, 74–5
Hydrocephalus vs. neoplastic hydrocephalus, *May*, 346
Hydrocortisone in adrenal crisis, *Feb.*, 215
Hygroma, cystic. See also *Lymphangioma, cavernous*.
of axilla, *May*, 530–35
of groin, *May*, 530–35
of neck, *May*, 530–35
of soft tissues, *May*, 552
Hypaque. See *Diatrizoate sodium*.
Hypercalcemia, idiopathic, vs. hyperparathyroidism, *May*, 591
Hyperkalemia in acute renal failure, *Feb.*, 135
Hypernatremia. See *Dehydration, hypernatremic*.
Hypernephroma, *May*, 485
Hyperosmolarity, signs and symptoms, *Feb.*, 202
Hyperuricemia in acute leukemia, *May*, 624
Hyperventilation. See under *Respiration*.
Hypervitaminosis D vs. hyperparathyroidism, *May*, 591, 592
Hypocalcemia in acute renal failure, *Feb.*, 136
Hypohydration. See *Dehydration*.
Hyponatremia, asymptomatic, clinical considerations, *Feb.*, 91
in acute renal failure, *Feb.*, 135
water intoxication with, *Feb.*, 85
Hypopotassemia, physical signs, *Feb.*, 103

ILEOSTOMY patient, sodium, chloride and potassium content of gastric juice in, *Feb.*, 162

Infections, clinical features, general, *Feb.*, 149–50
factors in, common, *Feb.*, 140–50
specific, *Feb.*, 150–52
fulminating, adrenocortical failure due to, *Feb.*, 211–12
in acute leukemia, treatment, *May*, 615–16
metabolic reaction to, *Feb.*, **139–54**
relation of nutrition to, *Feb.*, 151
vs. Ewing's tumor, *May*, 567
Insulin in diabetic acidosis, *Feb.*, 118–19
Intake, aberrations of, in infections, *Feb.*, 150
Interstitial cell tumors, *May*, 502–503, 604
Intestines, duplications of, *May*, 404
polyp, distribution of, *May*, 422
small, tumors of, *May*, 418–20
Intoxication, salicylate, *Feb.*, **281–99**
water. See under *Water*.
Intracellular fluid. See under *Fluids, body*.
Ions, concentration, physical signs of, *Feb.*, 103
Islet cell tumors, *May*, 423, 424
Isosthenuria, *Feb.*, 125

KETO-ACIDOSIS. See *Diabetes mellitus, acidosis*.
Kidneys, compensatory mechanisms, *Feb.*, 127
disease, fluid therapy, *Feb.*, **123–37**
failure, acute, fluid therapy, *Feb.*, 133–6
chronic, fluid therapy, *Feb.*, 132–3
filtration rate, general considerations, *Feb.*, 48–50
function of, current concepts, *Feb.*, 48–51
maturation of, *Feb.*, 51–6
glomeruli. See also *Nephritis, glomerular*.
filtration rate in first month, *Feb.*, 52
structure of, *Feb.*, 44–8
imbalance between glomerular filtration and tubular reabsorption, *Feb.*, 124
in maintenance of pH, *Feb.*, 22–4
pathology, types of, *Feb.*, 124–7
pelvis, tumors of, *May*, 486–7
structure, and function, relation to regulation of body fluids, *Feb.*, **43–80**
Kidneys, tubules, defects of, *Feb.*, 125, 127
functions of, general considerations, *Feb.*, 50–51
structure of, *Feb.*, 48
tumors, *May*, **473–90**
benign, *May*, 487
water loss, in hypernatremic dehydration, *Feb.*, 195

LABORATORY techniques, bedside, *Feb.*, **317–20**
Lanatoside C in congestive cardiac failure, *Feb.*, 249, 250
Larynx, tumors of, *May*, 374
Leiomyosarcoma, *May*, 548
Letterer-Siwe disease vs. bone tumor, *May*, 568, 569
Leukemia, acute, *May*, 612–27
clinical manifestations, *May*, 612–14
treatment, *May*, 614–27
chemotherapy, *May*, 616–24
supportive, *May*, 614–16
survivals, *May*, 627
vs. chronic granulocytic leukemia, *May*, 628
and lymphoma, *May*, **611–38**
granulocytic, chronic, *May*, 627–30
clinical manifestations, *May*, 627–8
treatment, *May*, 628–30
lymphatic, *May*, 392
vs. Ewing's tumor, *May*, 567–8
Leukeran. See *Chlorambucil*.
Levarterenol in adrenal crisis, *Feb.*, 215, 216
Levophed. See *Levarterenol*.
Lipid metabolism, disturbance in, in salicylate intoxication, *Feb.*, 284–5
Lipoma, of parotid gland, *May*, 369
of soft tissues, *May*, 552
Liver, cysts, nonparasitic, *May*, 439–41
engorgement, in congestive cardiac failure, *Feb.*, 244
hyperplasia of, nodular, focal, *May*, 441
tumors, *May*, **427–47**
benign, *May*, 436–43
diagnostic problems, *May*, 431
distribution, *May*, 430
malignant, *May*, 431–6
metastatic, *May*, 430
relation of metabolic disorders to, *May*, 444

Lungs, alveolar ventilation, increase in, due to salicylate intoxication, *Feb.*, 282–3
Luteoma. See *Adrenals, tumors, rest.*
Lye stricture of esophagus, *May*, 416
Lymphangiectasia, *May*, 537
Lymphangioma, *May*, **529–41**
cavernous, *May*, 387
in oral cavity, *May*, 373
mediastinal, *May*, 387
Lymph nodes, mediastinal, inflammatory lesions, *May*, 392–6
Lymphoma, malignant, of small intestine, *May*, 419
mediastinal, *May*, 387, 392
Lymphosarcoma. See under *Sarcoma.*

MAGNESIUM, content, of body, *Feb.*, 9, 13–14
requirements, *Feb.*, 38
Masculinovoblastoma. See *Adrenals, tumors, rest.*
Mediastinum, anatomic contents, *May*, 381
anterior, contents, *May*, 381
mass lesions in, *May*, 381–92
masses in, differential diagnosis, *May*, **379–412**
location, *May*, 381
middle, contents, *May*, 381
mass lesions in, *May*, 392–400
posterior, contents, *May*, 381
mass lesions in, *May*, 400–10
teratoma of, *May*, 577–8
Medulloblastoma, *May*, 354
Membranes, cell, metabolic transfer across, *Feb.*, 150–51
Meningocele, mediastinal, *May*, 410
Meralluride in congestive cardiac failure, *Feb.*, 251
Mercaptopurine, in acute leukemia, *May*, 617
in chronic granulocytic leukemia, *May*, 629
Mercuhydrin. See *Meralluride.*
Mesenchymoma. See *Mesodermal tumor, mixed.*
Mesentery, lymphatic cyst, *May*, 535–7
Mesodermal tumor, mixed, *May*, 549–52
Metabolic reaction to infectious disease, *Feb.*, **139–54**
Metabolism, basal, correlation with surface area, *Feb.*, 33, 34
disorders of, relation to liver tumors, *May*, 444
Metabolism, rate of, increase in, in salicylate intoxication, *Feb.*, 284
total, *Feb.*, 33
Metaraminol bitartrate in adrenal crisis, *Feb.*, 216
Methchlorethamine hydrochloride in Hodgkin's disease, *May*, 631
Methotrexate. See *Amethopterin.*
Microhematocrit test in diabetic acidosis, *Feb.*, 118
Morphine, in burns, *Feb.*, 172, 173
in cardiac failure, *Feb.*, 254
Mortality from neoplasms, *May*, 449
Mouth, tumors of, *May*, 369–74
Murmurs. See under *Heart.*
Mustargen Hydrochloride. See *Methchlorethamine hydrochloride.*
Myleran. See *Busulfan.*
Myoblastoma of tongue, *May*, 373

NASOPHARYNX, angiofibroma, juvenile, *May*, 371, 372
carcinoma, *May*, 370
Neck, and head, tumors of, *May*, **367–78**
cystic hygroma, *May*, 530–35
teratoma of, *May*, 576–7
Neoplasms. See also *Carcinoma; Sarcoma; Tumors;* and organ or region affected.
benign, of bone, vs. bone tumor, *May*, 569
clinical manifestations, *May*, 338
etiology, *May*, 338
general considerations, *May*, **337–41**
incidence, *May*, 337
malignancy, pathologic criteria of, *May*, 339
mortality from, *May*, 449
prognosis, *May*, 340
sites of, *May*, 449
sites of origin, *May*, 339
treatment, *May*, 340, 341
types, *May*, 339, 349
Neoplastic diseases, symposium on, *May*, **337–638**
Nephrectomy in nephroblastoma, *May*, 481, 482
Nephritis, glomerular, acute, fluid therapy in, *Feb.*, 128–9
Nephroblastoma, *May*, 474–85
age incidence, *May*, 474
clinical manifestations, *May*, 474–5
diagnosis, *May*, 476–80
hereditary factors, *May*, 475
histogenesis, *May*, 474
location, *May*, 475

Nephroblastoma, metastases, treatment of, *May*, **483**
prognosis, *May*, 485
sex incidence, *May*, 475
symptoms and signs, *May*, 475–6
treatment, *May*, 480–84
Nephron-destroying disease, progressive, *Feb.*, 124, 125
Nephrosis, lower nephron, urine concentration in, *Feb.*, 64, 65
Nephrotic syndrome, fluid therapy, *Feb.*, 129–32
Nerve fibers, medullated, vs. retinoblastoma, *May*, 361
Nervous system, central, tumors of, *May*, **343–58**
air contrast studies, *May*, 351–2
cerebral angiography, *May*, 352
diagnosis, *May*, 344–9
in childhood, *May*, 346
in infancy, *May*, 346
in preadolescent and adolescent periods, *May*, 348
electroencephalography, *May*, 349–50
incidence, *May*, 344
infratentorial, *May*, 347
ophthalmologic examination, *May*, 349
supratentorial, *May*, 347–8
treatment, *May*, 343
types, *May*, 352–7
x-ray examination, *May*, 350–52
Neurenteric cyst, *May*, 404–406
Neurilemmoma, *May*, 548
Neuroblastoma, *May*, **449–72**
age incidence, *May*, 450
autopsy findings, *May*, 453
clinical manifestations, *May*, 451–2
mediastinal, *May*, 400, 402, 403
metastasis, *May*, 452, 453
metastatic, vs. Ewing's tumor, *May*, 567
origin, sites of, *May*, 450–51
pathology, *May*, 452–3
prognosis, *May*, 453–70
relation of metastases, site of origin and age at onset to, *May*, 466
relation of site of origin and treatment to, *May*, 469
sex incidence, *May*, 450
treatment, *May*, 453–70
results of, *May*, 455
survival after, *May*, 456
vitamin B_{12} in, *May*, 457–65
Neuroepithelioma, *May*, 363
Neurofibroma of tongue, *May*, 373
Neurogenic tumors of mediastinum, *May*, 400–403
Neurologic disease, fluid therapy in, complications of, *Feb.*, **257–79**
Neurosurgery, fluid therapy in, *Feb.*, 165
Nevi, strawberry, incidence of, *May*, 527
Newborn, adrenal hemorrhage in, *Feb.*, 211
caloric requirements, daily, *Feb.*, 185
clinical appraisal, *Feb.*, 181–2
electrolyte content of gastrointestinal fluids in, *Feb.*, 188
electrolyte needs, *Feb.*, 181–4
electrolyte requirements, *Feb.*, 186
fluid therapy in, *Feb.*, **181–92**
laboratory data, *Feb.*, 182–4
water requirements, *Feb.*, 186
Nitrogen, excretion, *Feb.*, 53
solutions for provision of, *Feb.*, 308
Nitrogen mustard, in chronic granulocytic leukemia, *May*, 629
in Hodgkin's disease, *May*, 631, 634
Norepinephrine. See *Levarterenol*.
Nose. See also *Nasopharynx*.
cavity, tumors of, *May*, 369–74
teratoma of, *May*, 576
Nutrition, relation to infection, *Feb.*, 151

Odontoma, *May*, 375
Olfactory neuroepithelial tumor, *May*, 370, 371
Oliguria. See *Urine, suppression*.
Omentum, lymphatic cyst, *May*, 535–7
Ophthalmologic examination in tumors of central nervous system, *May*, 349
Optic nerve head, drusen of, vs. retinoblastoma, *May*, 362, 363
Oral. See *Mouth; Teeth*.
Orthopnea in congestive cardiac failure, *Feb.*, 243
Osteoma, osteoid, vs. osteosarcoma, *May*, 569
Osteosarcoma. See under *Sarcoma*.
Ovary, teratoma of, *May*, 578
tumors, *May*, 491–500, 599–604
androgen-producing, *May*, 602–604
estrogen-producing, *May*, 599–602
Oxygen therapy in cardiac failure, *Feb.*, 254

Palate, teratoma of, *May*, 576
Pancreas, and gastrointestinal tract, tumors of, *May*, **413–26**
cysts, *May*, 423

Pancreas, ectopic tissue in stomach, *May*, 424
fibrosis, cystic, diagnosis, *Feb.*, 225–7
electrolyte abnormality in, *Feb.*, **221–40**
tumors, *May*, 423–4
Papilloma, nasal, *May*, 369
of choroid plexus, *May*, 356, 357
of larynx, *May*, 374
Paraganglioma, nonchromaffin. See *Chemodectoma.*
Paraldehyde in convulsions due to hypernatremic dehydration, *Feb.*, 198
Parathyroid glands, tumors, *May*, 590–92
differential diagnosis, *May*, 591–2
laboratory studies, *May*, 591
treatment, *May*, 592
Parent counselling in hemangiomas, *May*, 524
Parenteral fluids. See under *Fluids.*
Parotid gland, fibrosarcoma, *May*, 369
hemangioma, *May*, 368, 369
lipoma, *May*, 369
Parotitis, chronic, vs. neoplasm, *May*, 367
Pathology, renal, types of, *Feb.*, 124–7
Percorten. See *Desoxycorticosterone trimethylacetate.*
Pericardium, cyst of, *May*, 387–8
Peutz-Jeghers syndrome, *May*, 418, 419
pH, body mechanisms for maintenance of, *Feb.*, 20–24
Pharynx, tumors of, *May*, 369–74
Phenobarbital sodium in convulsions due to hypernatremic dehydration, *Feb.*, 198
Phentolamine in diagnosis of pheochromocytoma, *May*, 598
Pheochromocytoma, *May*, 597–9
diagnosis, *May*, 598
laboratory data, *May*, 598
treatment, *May*, 598–9
Phosphate, excretion, in maintenance of pH, *Feb.*, 23–4
requirements, *Feb.*, 38
Phosphoric acid in maintenance of pH, *Feb.*, 22
Phosphorus, content, of body, *Feb.*, 9, 15–16
kidney filtration rate, *Feb.*, 126
Pinealoma, *May*, 575
Pituitary gland, tumors, *May*, 584–5
Plasma. See under *Blood.*
Pneumoencephalography. See under *Brain.*
Poisoning, salt, in hypernatermic dehydration, *Feb.*, 195
Polyp, in colon, *May*, 421
intestinal, distribution of, *May*, 422
nasal, *May*, 369
Polyposis, multiple, hereditary, of colon, *May*, 421, 422
Position in cardiac failure, *Feb.*, 254
Potassium, administration of, contraindications, *Feb.*, 95
content, of body, *Feb.*, 9, 13
of gastric juice in ileostomy patients, *Feb.*, 162
deficits, and intracellular dehydration, *Feb.*, 92–6
in salicylate poisoning, repair of, *Feb.*, 294, 295
urine concentration in, *Feb.*, 66, 67
with metabolic alkalosis, urine and body fluids in, *Feb.*, 73
excretion, *Feb.*, 53
in chronic renal failure, *Feb.*, 133
in diabetic acidosis, *Feb.*, 119, 120, 121
in fluid therapy, after appendectomy, *Feb.*, **161**
after herniorrhaphy, *Feb.*, 161
of diarrhea in newborn, *Feb.*, 190
in isotonic dehydration, *Feb.*, 109
in preoperative fluid therapy, *Feb.*, 158
in newborn, *Feb.*, 159
in salicylate poisoning, *Feb.*, 294, 295
infusion, urine and body fluids in, *Feb.*, 73
intake, correlated with body content and growth requirements, *Feb.*, 9
level, serum, bedside test for, *Feb.*, 317, 318
loss, salt depletion and dehydration, theoretical considerations, *Feb.*, **81–98**
replacement by other cations, *Feb.*, 93–6
requirements, *Feb.*, 37–8
in diarrhea with dehydration, *Feb.*, 39
in parenteral fluids, *Feb.*, 32, 33
solution, in dehydration, *Feb.*, 95
in potassium deficiency, *Feb.*, 37, 38
Potassium acetate in hypertonic dehydration due to diarrhea, *Feb.*, 108
Potassium bicarbonate in diarrhea, *Feb.*, 111
Potassium chloride, in fluid therapy in newborn, *Feb.*, 187
in hypernatremic dehydration, *Feb.*, 198
solution, in dehydration due to hypertrophic pyloric stenosis, *Feb.* 113

Prednisolone, in acute leukemia, *May*, 617
Prednisone, in acute leukemia, *May*, 617
in Hodgkin's disease, *May*, 634
Prematurity, retinopathy of. See *Retrolental fibroplasia.*
Progonoma, melanotic, *May*, 375
Prostate, tumors, *May*, 504–507
Protein, plasma, increase in, solutions for, *Feb.*, 309–10
serum, in maintenance of pH, *Feb.*, 22
solutions, excessive administration, in hypernatremic dehydration, *Feb.*, 194–5
Puberty, precocious, *May*, 599*ff.*
Pulmonary. See also *Lungs.*
arteries, aneurysm, *May*, 398, 400
Purinethol. See *Mercaptopurine.*
Pyloric stenosis. See *Pylorus, stenosis of.*
Pylorus, stenosis of, acidosis due to, *Feb.*, 24
hypertrophic, deficit therapy in dehydration due to, *Feb.*, 113
fluid therapy, *Feb.*, 112
vs. stomach tumor, *May*, 417, 418
water and electrolyte deficits in, *Feb.*, 100

RADIATION in nephrectomy, *May*, 481
Reaction, metabolic, to infectious disease, *Feb.*, **139–54**
stress, in infections, *Feb.*, 140–43
Rectum, fluid therapy infusion, *Feb.*, 311
tumors, *May*, 420–23
Regitine. See *Phentolamine.*
Renal. See *Kidneys.*
Respiration, depression of, in salicylate poisoning, *Feb.*, 298
hyperventilation, acidosis due to, *Feb.*, 24, 25
in congestive cardiac failure, *Feb.*, 243
Respiratory tract, infections, treatment, in cardiac failure, *Feb.*, 254
obstruction, acidosis due to, *Feb.*, 24
Rest, bed, in cardiac failure, *Feb.*, 253
Reticuloendothelioses vs. bone tumor, *May*, 568–9
Reticulum cell sarcoma. See under *Sarcoma.*
Retina, drusen of, vs. retinoblastoma, *May*, 362, 363
fibrosis of, massive, vs. retinoblastoma, *May*, 361
Retinitis, metastatic, vs. retinoblastoma, *May*, 360
Retinoblastoma, *May*, **359–65**
clinical signs, *May*, 359
diagnosis, *May*, 359
differential diagnosis, *May*, 359–63
histopathology, *May*, 363–4
prognosis, *May*, 364–5
treatment, *May*, 364
Retinopathy of prematurity. See *Retrolental fibroplasia.*
Retrolental fibroplasia vs. retinoblastoma, *May*, 360, 361
Retroperitoneum, teratoma of, *May*, 578
Rhabdomyosarcoma. See under *Sarcoma.*
Ringer's lactate solution, in acute renal failure, *Feb.*, 134
in diarrhea in newborn, *Feb.*, 190
in hypertonic dehydration, *Feb.*, 110
due to diarrhea, *Feb.*, 108
in hypotonic dehydration due to diarrhea, *Feb.*, 107
in isotonic dehydration, *Feb.*, 89
due to diarrhea, *Feb.*, 105
in nephrotic syndrome, *Feb.*, 130
Roentgen examination in tumors of central nervous system, *May*, 350–52
Roentgen therapy, in acute leukemia, *May*, 625, 627
in chronic granulocytic leukemia, *May*, 628, 629
in hemangioma, *May*, 523–4
in Hodgkin's disease, *May*, 634
in nephroblastoma, *May*, 482
in retinoblastoma, *May*, 364

SACROCOCCYX, teratoma of, *May*, 578–82
Salicylate, determination, bedside test for, *Feb.*, 319, 320
eradication of, *Feb.*, 296–7
intoxication, *Feb.*, **281–99**
toxic amounts, basic effects, *Feb.*, 281–5
Saline, in fluid therapy, in newborn, *Feb.*, 187
of burns, *Feb.*, 176
in operative period fluid therapy, *Feb.*, 160
solution. See also *Sodium chloride.*
in acute renal failure, *Feb.*, 134, 135
in adrenocortical failure, *Feb.*, 214
in diabetic acidosis, *Feb.*, 120
in heat prostration, *Feb.*, 236
in hypernatremic dehydration, *Feb.*, 197

Saline solution, in isotonic dehydration, *Feb.*, 36, 89
in nephrotic syndrome, *Feb.*, 130
in preoperative fluid therapy, *Feb.*, 158
Saliva, electrolytes, in cystic fibrosis of pancreas, *Feb.*, 223
Salivary glands, major, tumors of, *May*, 367–9
minor, tumors of, *May*, 370
Salt. See also *Sodium chloride.*
and water loss, proportional. See *Dehydration, isotonic.*
depletion, in cystic fibrosis of pancreas, *Feb.*, 232–5
potassium loss and dehydration, theoretical considerations, *Feb.*, 81–98
in prevention of heat prostration in cystic fibrosis of pancreas, *Feb.*, 235
poisoning, in hypernatremic dehydration, *Feb.*, 195
restriction, in cardiac failure, *Feb.*, 253
in glomerulonephritis, *Feb.*, 128, 129
retention, without water, *Feb.*, 87
Sarcoidosis, *May*, 392, 396
Sarcoma, fibrosarcoma, of parotid gland, *May*, 369
of soft tissues, *May*, 548–9
lymphosarcoma, *May*, 633–5
clinical manifestations, *May*, 633–4
mediastinal, *May*, 387, 392
treatment, *May*, 634–5
mesodermal, mixed, *May*, 505
osteosarcoma, *May*, 561–4
classes, *May*, 562, 563
prognosis, *May*, 564
roentgen findings, *May*, 562
symptoms, *May*, 562
treatment, *May*, 563
reticulum cell, *May*, 633–5
primary, of bone, vs. Ewing's tumor, *May*, 568
rhabdomyosarcoma, alveolar. See *Rhabdomyosarcoma, embryonal*, under *Sarcoma.*
embryonal, *May*, 546
of head and neck, *May*, 371
of soft tissues, *May*, 546–8
Sarcoma botryoides, *May*, 371, 505, 548
Serum, albumin, in nephrotic syndrome, *Feb.*, 130
bicarbonate, measurement, *Feb.*, 19
potassium level, bedside test for, *Feb.*, 317, 318
proteins, in maintenance of pH, *Feb.*, 22
Shock, fluid therapy, *Feb.*, 177–9
Shwachman plate test, correlation with sweat chloride, *Feb.*, 231
Sinus, nasal, tumors of, *May*, 369–74
Skin, appendage, tumors of, *May*, 376
tumors of, *May*, 376–7
Skull. See *Cranium.*
Sodium, content, of body, *Feb.*, 9, 10–12
of gastric juice in ileostomy patients, *Feb.*, 162
excretion, *Feb.*, 53
in fluid therapy, after appendectomy, *Feb.*, 161
after herniorrhaphy, *Feb.*, 161
of diarrhea in newborn, *Feb.*, 190
in preoperative fluid therapy, *Feb.*, 158
in newborn, *Feb.*, 159
in salicylate poisoning, *Feb.*, 293
in sweat in cystic fibrosis of pancreas, *Feb.*, 222
intake, correlated with body content and growth requirements, *Feb.*, 9
kidney filtration rate, *Feb.*, 126
requirements, *Feb.*, 34–7
in diarrhea with dehydration, *Feb.*, 39
in parenteral fluids, *Feb.*, 32, 33
tubular transport, *Feb.*, 50, 51
Sodium bicarbonate, in diabetic acidosis, *Feb.*, 120, 121
in fluid therapy of diarrhea in newborn, *Feb.*, 190
in salicylate poisoning, *Feb.*, 293, 295
reabsorption, acidification of urine due to, *Feb.*, 71
serum, measurement of, *Feb.*, 19
Sodium chloride. See also *Saline solution; Salt.*
in adrenocortical failure, *Feb.*, 214
in diabetic acidosis, *Feb.*, 119
in diarrhea, *Feb.*, 111
in fluid therapy in newborn, *Feb.*, 187
in hypernatremic dehydration, *Feb.*, 198
solution, in acute renal failure, *Feb.*, 136
in chronic renal failure, *Feb.*, 132
in dehydration due to hypertrophic pyloric stenosis, *Feb.*, 113
in diabetic acidosis, *Feb.*, 121
Sodium lactate, in fluid therapy, of diarrhea in newborn, *Feb.*, 190
of burns, *Feb.*, 176

Sodium lactate, in hypernatremic dehydration, *Feb.*, 197, 198
solution, in chronic renal failure, *Feb.*, 132
in diabetic acidosis, *Feb.*, 120, 121
in hypertonic dehydration due to diarrhea, *Feb.*, 108
Solu-cortef. See *Hydrocortisone.*
Solute concentration, decreased, *Feb.*, 88
in fasting infant, *Feb.*, 54
increase in, *Feb.*, 88
Solutions. See *Fluid* and specific solutions.
Sounds. See under *Heart.*
Steroids, adrenal, in acute leukemia, *May*, 617
adrenocortical, in renal regulation of body fluids, *Feb.*, 74, 75
discontinuance of, adrenocortical failure due to, *Feb.*, 212
Stomach, ectopic pancreatic tissue in, *May*, 424
secretion, sodium, chloride and potassium content of, *Feb.*, 162
tumors, *May*, 416–18
clinical manifestations, *May*, 417
treatment, *May*, 418
Stools. See *Feces.*
Strawberry nevi, incidence, *May*, 527
Stress reaction in infections, *Feb.*, 140–43
Sucrose in diarrhea, *Feb.*, 111
Surgery, elective, preoperative fluid therapy in, *Feb.*, 157–9
Surgical conditions, fluid therapy in, *Feb.*, **155–67**
Sweat, chlorides, correlation with Shwachman plate test, *Feb.*, 231
screening tests, *Feb.*, 230–31
collection, in cystic fibrosis of pancreas, *Feb.*, 229–30
electrolytes, concentration of, *Feb.*, 228
content, *Feb.*, 146
in cystic fibrosis of pancreas, *Feb.*, 221–4
secretion, factors controlling, *Feb.*, 227–9
test, in diagnosis of cystic fibrosis of pancreas, *Feb.*, 225
Syndrome, dilution, *Feb.*, 252
low-salt, *Feb.*, 252
Synovioma, *May*, 548
Syringocystadenoma papilliferans, *May*, 376

TEARS, electrolytes, in cystic fibrosis of pancreas, *Feb.*, 224
Teeth, tumors of, *May*, 374–5
TEM. See *Triethylene melamine.*
Teratoma, *May*, **573–82**
benign, *May*, 385
ectodermal, *May*, 574
endodermal, *May*, 574
in base of skull, *May*, 576
in head and neck, *May*, 373
intracardiac, *May*, 577
malignant, *May*, 385
mediastinal, *May*, 384–7, 577–8
mesodermal, *May*, 574
nasal, *May*, 576
of neck, *May*, 576–7
of thyroid, *May*, 576–7
ovarian, *May*, 491–5, 578, 600
diagnosis, *May*, 494
incidence, *May*, 494
prognosis, *May*, 494, 495
symptoms, *May*, 494
treatment, *May*, 494
palatal, *May*, 576
pineal, *May*, 575–6
retroperitoneal, *May*, 578
sacrococcygeal, *May*, 578–82
testicular, *May*, 501–502
Testicles. See *Testes.*
Testes, tumors, *May*, 500–504, 604
metastatic, *May*, 503–504
Thrombocytopenia complicating hemangioma, *May*, 522
Thymoma, *May*, 384
Thymus, enlargement of, *May*, 381–4
vs. teratoma, *May*, 387
Thyroid, lingual, *May*, 373, 374
teratoma, *May*, 576–7
tumors, *May*, 585–9
clinical manifestations, *May*, 586–7
etiology, *May*, 587–9
incidence, *May*, 585–6
treatment, *May*, 589
types, *May*, 586
Tissue, catabolism, in potassium deficits, *Feb.*, 92
fibrous, tumors of, *May*, 552
soft, tumors of, *May*, **543–55**
benign, *May*, 552–3
incidence, *May*, 543–4
malignant, *May*, 544–52
origin, *May*, 544
treatment, *May*, 553–4
undifferentiated, *May*, 544–5
Tongue, hemangioma, *May*, 373
myoblastoma, *May*, 373
neurofibroma, *May*, 373

Toxoplasmosis vs. retinoblastoma, *May*, 361
Tracheobronchi, electrolytes, in cystic fibrosis of pancreas, *Feb.*, 224
Transfusion, blood. See under *Blood*.
Trauma, fluid therapy, *Feb.*, 177–9
vs. bone tumor, *May*, 566
Trichoepithelioma, *May*, 376
Triethylene melamine in retinoblastoma, *May*, 364
Tuberculosis, lymph node enlargement due to, *May*, 392
Tumors. See also under specific organs and regions.
adrenal rest, *May*, 603–604
adrenocortical, feminizing, *May*, 595–6
virilizing, *May*, 592–3
androgen-producing, *May*, 602–604
Brenner, *May*, 500
carcinoid, of small intestine, *May*, 419
Codman's. See *Chondroblastoma, benign.*
Ewing's, *May*, 564–6
granulosa cell, *May*, 497–8, 600
Grawitz's. See *Hypernephroma.*
infratentorial, *May*, 347
interstitial cell, *May*, 502–503, 604
islet cell, *May*, 423, 424
mesodermal, mixed, *May*, 549–52
neuroepithelial, olfactory, *May*, 370, 371
neurogenic, of mediastinum, *May*, 400–403
of abdomen, analysis of, *May*, 414
of adrenal cortex, *May*, 592–7
of adrenal medulla, *May*, 597–9
of appendix, *May*, 420
of bladder, *May*, 504–507
of bone, *May*, **557–71**
of central nervous system, *May*, **343–58**
of cervix, *May*, 504–507
of choroid plexus, *May*, 356–7
of colon, *May*, 420–23
of dental origin, *May*, 374–5
of ear, *May*, 369–74
of endocrine glands, *May*, **583–608**
of esophagus, *May*, 415–16
of fibrous tissue, *May*, 552
of genitourinary tract, lower, *May*, **491–509**
of head and neck, *May*, **367–78**
of intestine, small, *May*, 418–20
of kidney, *May*, **473–90**
of larynx, *May*, 374
of liver, *May*, **427–47**
of nasal cavity, *May*, 369–74
Tumors, of oral cavity, *May*, 369–74
of ovary, *May*, 491–500, 599–604
of pancreas, *May*, 423–4
of parathyroid glands, *May*, 590–92
of pharynx, *May*, 369–74
of pituitary gland, *May*, 584–5
of prostate, *May*, 504–507
of rectum, *May*, 420–23
of renal pelvis, *May*, 486–7
of salivary glands, major, *May*, 367–9
minor, *May*, 370
of skin, *May*, 376–7
of skin appendage origin, *May*, 376
of soft tissues, *May*, **543–55**
of stomach, *May*, 416–18
of testes, *May*, 500–504, 604
of thyroid gland, *May*, 585–9
of tunica vaginalis, *May*, 504
of vagina, *May*, 504–507
retinal anlage, *May*, 375
supratentorial, *May*, 347–8
turban. See *Cylindroma.*
Warthin, *May*, 368
Wilms'. See *Nephroblastoma.*
Tunica vaginalis, tumors of, *May*, 504
Tunica vasculosa lentis vs. retinoblastoma, *May*, 359, 360
Turban tumor. See *Cylindroma.*

Urea, kidney filtration rate, *Feb.*, 126
Urine, acidification, *Feb.*, 69–73
concentration, *Feb.*, 56–67
excretion, in burns, *Feb.*, 175
formation, cessation of, *Feb.*, 125
in acid-base disturbances, *Feb.*, 73
suppression of, postdialysis, *Feb.*, 127

Vagina, tumors, *May*, 504–507
Veins, cannulation, *Feb.*, 313–14
Venesection, *Feb.*, 322–5
Venoclysis, *Feb.*, 312
Ventilation, alveolar, pulmonary, in salicylate intoxication. *Feb.*, 282–3
Ventriculography, in tumors of central nervous system, *May*, 351, 352
Vitamin B_{12}. See *Cyanocobalamin.*
Vomiting, and diarrhea, fluid therapy, *Feb.*, **99–114**

Warthin tumor. See *Cystadenoma lymphomatosum, papillary.*

Water, administration, in dehydration, *Feb.*, 95, 96
and salt loss, proportional. See *Dehydration, isotonic.*
balance, in fasting infant, *Feb.*, 54
body, total, and normal electrolyte composition, *Feb.*, 5–18
conservation, antidiuretic hormone in, *Feb.*, 60, 61
content, of body, *Feb.*, 8, 9, 10
deficits, in dehydration, *Feb.*, 100
electrolyte-free, losses of, in hypernatremic dehydration, *Feb.*, 194
expenditure, *Feb.*, 29, 30, 31
intake, correlated with body content and growth requirements, *Feb.*, 9
oral, interference with, in hypernatremic dehydration, *Feb.*, 193–4
Water, intoxication, clinical considerations, *Feb.*, 91
in neurologic disease, *Feb.*, 257–79
with hyponatremia, *Feb.*, 85
losses, in stools, in hypernatremic dehydration, *Feb.*, 194
renal, in hypernatremic dehydration, *Feb.*, 195
requirements, in diarrhea with dehydration, *Feb.*, 39
in newborn, *Feb.*, 186
salt retention without, *Feb.*, 87
solutions for provisions of, *Feb.*, 304–307
Wilms' tumor. See *Nephroblastoma.*

X-RAYS. See *Roentgen.*